A Phase 2 interventional study of Ramucirumab in Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, sponsored by Eli Lilly and Company. Completed at 45 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-29.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing ramucirumab in Stomach Neoplasms — 3 open to participants now, 4 under way, none of them phase 3. Ramucirumab · Stomach Neoplasms.
Among the 20 studies testing ramucirumab in Stomach Neoplasms, this one is the 7th largest by enrollment, is one of 2 that started in 2015, is one of 10 in phase 2, and was the 5th registered.
3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.
Browse Stomach Neoplasms studies →3 of the 20 studies testing ramucirumab in Stomach Neoplasms are open now, in 3 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
Yonsei University · Sites in Korea, Republic of
Ages 19+
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 15–75
By country, each count listing its studies:
Ramucirumab: first FDA approval 2014 (CYRAMZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 15 · Phase 3 4
First in 2009; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 164 is above the median of 66 across 2,502 interventional studies indexed under Stomach Neoplasms.
Median enrollment 59 across the 20 interventional studies. Of the 12 that completed or were terminated, 9 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 20 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
17 studies in Stomach Neoplasms by Eli Lilly and Company: 3 open now, 3 under way, none of them phase 3. Of 12 finished, 10 (83%) have results posted.
Among the 17 studies in Stomach Neoplasms by Eli Lilly and Company, this one is the 8th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2015, is one of 7 in phase 2, and was the 12th registered.
Eli Lilly and Company’s Stomach Neoplasms studies by the year they started, since 2004.
1 of the studies testing ramucirumab in Stomach Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07669740The First Affiliated Hospital with Nanjing Medical UniversityA Study on the Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients With Short-term Recurrence After Adjuvant Therapy | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing ramucirumab in Stomach Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 17 in Stomach Neoplasms:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study was to evaluate the safety and pharmacokinetics of administering various dose regimens of ramucirumab in participants with advanced gastric cancer whose disease has progressed during or following prior chemotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The participant received combination chemotherapy prior to disease progression.
The participant has adequate organ function, including:
Exclusion Criteria:
The participant is receiving chronic therapy with any of the following within 7 days prior to randomization:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Standard dose of 8 milligram per kilogram (mg/kg) ramucirumab given intravenously (IV) on day 1 and day 15 of each cycle (28-day cycle) until discontinuation criteria are met.
Drug: Ramucirumab
Experimental dose of 12 mg/kg ramucirumab given IV on day 1 and day 15 of each cycle (28-day cycle) until discontinuation criteria are met.
Drug: Ramucirumab
Experimental dose of 6 mg/kg ramucirumab given IV on day 1, 8, 15 and 22 of each cycle (28-day cycle) until discontinuation criteria are met.
Drug: Ramucirumab
Experimental dose of 8 mg/kg ramucirumab given IV on day 1 and day 8 of each cycle (21-day cycle) until discontinuation criteria are met.
Drug: Ramucirumab
Administered IV
Also known as: LY3009806, IMC-1121B
Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab
The Cmin is the minimum observed serum concentration of ramucirumab.
Time frame: Day 29, 43, 71 and 85: predose
Immunogenicity: Number of Participants With Anti-Ramucirumab Antibodies
Number of participants with positive treatment emergent anti-ramucirumab antibodies was summarized by treatment group. A treatment-emergent anti-drug antibodies (TEADA) sample was defined as: a post treatment sample with at least a 4-fold increase in titer from pre treatment sample; or 1:20 post treatment titer for participants that had no detectable ADA titer at baseline.
Time frame: Predose Cycle 1 Through Short Term Follow Up (Up to 5 Months)
Rate of Progression Free Survival (PFS) at the First 6-Week Tumor Assessment
PFS defined as the time from first day of therapy to first evidence of disease progression per response evaluation criteria in solid tumors version 1.1 (RECIST v1.1) or death from any cause up to the first 6-week tumor assessment. Progressive Disease (PD) is at least 20% increase in sum of diameters of target lesions,taking as reference smallest sum on study and absolute increase of at least 5 mm.Appearance of 1 or more new lesions was also considered progression. Nontarget PD is unequivocal progression of existing nontarget lesions.Appearance of 1 or more new nontarget lesions was also considered PD.Participants with no baseline disease assessment: PFS time was censored at the randomization date,regardless of whether or not objectively determined disease progression or death has been observed.
Time frame: Baseline until the first 6-week tumor assessment
| Milestone | Ramucirumab Regimen 1 | Ramucirumab Regimen 2 | Ramucirumab Regimen 3 | Ramucirumab Regimen 4 |
|---|---|---|---|---|
| Started | 40 | 42 | 41 | 41 |
| Received at least one dose of study drug | 38 | 42 | 41 | 40 |
| Completed | 34 | 38 | 40 | 36 |
| Not completed | 6 | 4 | 1 | 5 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 3 | 2 | 1 | 0 |
| Withdrew: Physician decision | 1 | 1 | 0 | 3 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 2 |
| Withdrew: Randomized, but never treated | 1 | 0 | 0 | 0 |
The Cmin is the minimum observed serum concentration of ramucirumab.
| microgram per milliliter (µg/mL) | Ramucirumab Regimen 1 | Ramucirumab Regimen 2 | Ramucirumab Regimen 3 | Ramucirumab Regimen 4 |
|---|---|---|---|---|
| Day 29 | 32.9 ± 51 | 59.5 ± 60 | 69.3 ± 45 | 71.6 ± 37 |
| Day 43 | 47.6 ± 36 | 71.0 ± 58 | 83.0 ± 57 | 57.4 ± 44 |
| Day 71 | 60.4 ± 34 | 65.0 ± 60 | 122 ± 65 | 97.1 ± 46 |
| Day 85 | 64.3 ± 40 | 79.4 ± 46 | 125 ± 56 | 81.6 ± 50 |
Number of participants with positive treatment emergent anti-ramucirumab antibodies was summarized by treatment group. A treatment-emergent anti-drug antibodies (TEADA) sample was defined as: a post treatment sample with at least a 4-fold increase in titer from pre treatment sample; or 1:20 post treatment titer for participants that had no detectable ADA titer at baseline.
| Participants | Ramucirumab Regimen 1 | Ramucirumab Regimen 2 | Ramucirumab Regimen 3 | Ramucirumab Regimen 4 |
|---|---|---|---|---|
| Immunogenicity: Number of Participants With Anti-Ramucirumab Antibodies | 0 | 0 | 0 | 0 |
PFS defined as the time from first day of therapy to first evidence of disease progression per response evaluation criteria in solid tumors version 1.1 (RECIST v1.1) or death from any cause up to the first 6-week tumor assessment. Progressive Disease (PD) is at least 20% increase in sum of diameters of target lesions,taking as reference smallest sum on study and absolute increase of at least 5 mm.Appearance of 1 or more new lesions was also considered progression. Nontarget PD is unequivocal progression of existing nontarget lesions.Appearance of 1 or more new nontarget lesions was also considered PD.Participants with no baseline disease assessment: PFS time was censored at the randomization date,regardless of whether or not objectively determined disease progression or death has been observed.
| Percentage of participants | Ramucirumab Regimen 1 | Ramucirumab Regimen 2 | Ramucirumab Regimen 3 | Ramucirumab Regimen 4 |
|---|---|---|---|---|
| Rate of Progression Free Survival (PFS) at the First 6-Week Tumor Assessment | 43.9 (27.3 to 59.3) | 61.9 (44.9 to 75.0) | 53.0 (36.2 to 67.3) | 51.2 (34.2 to 65.9) |
Collected over Up To 3 Years and 3 Months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ramucirumab Regimen 1 | — | 10/38 (26.3%) | 30/38 (78.9%) |
| Ramucirumab Regimen 2 | — | 11/42 (26.2%) | 31/42 (73.8%) |
| Ramucirumab Regimen 3 | — | 10/41 (24.4%) | 36/41 (87.8%) |
| Ramucirumab Regimen 4 | — | 18/40 (45%) | 31/40 (77.5%) |
| Event | Ramucirumab Regimen 1 | Ramucirumab Regimen 2 | Ramucirumab Regimen 3 | Ramucirumab Regimen 4 |
|---|---|---|---|---|
| VomitingGastrointestinal disorders | 1/38 | 1/42 | 0/41 | 4/40 |
| Gastric haemorrhageGastrointestinal disorders | 0/38 | 0/42 | 3/41 | 0/40 |
| Non-cardiac chest painGeneral disorders | 2/38 | 0/42 | 0/41 | 0/40 |
| PyrexiaGeneral disorders | 2/38 | 0/42 | 0/41 | 0/40 |
| Abdominal painGastrointestinal disorders | 1/38 | 2/42 | 0/41 | 2/40 |
| DysphagiaGastrointestinal disorders | 0/38 | 1/42 | 1/41 | 2/40 |
| PneumoniaInfections and infestations | 0/38 | 2/42 | 0/41 | 1/40 |
| Cardiac arrestCardiac disorders | 1/38 | 1/42 | 0/41 | 0/40 |
| Duodenal ulcer haemorrhageGastrointestinal disorders | 1/38 | 0/42 | 0/41 | 0/40 |
| Gastric perforationGastrointestinal disorders | 1/38 | 0/42 | 0/41 | 0/40 |
| Event | Ramucirumab Regimen 1 | Ramucirumab Regimen 2 | Ramucirumab Regimen 3 | Ramucirumab Regimen 4 |
|---|---|---|---|---|
| FatigueGeneral disorders | 10/38 | 12/42 | 6/41 | 9/40 |
| Decreased appetiteMetabolism and nutrition disorders | 8/38 | 9/42 | 11/41 | 7/40 |
| Abdominal painGastrointestinal disorders | 6/38 | 10/42 | 7/41 | 4/40 |
| DiarrhoeaGastrointestinal disorders | 3/38 | 9/42 | 4/41 | 5/40 |
| VomitingGastrointestinal disorders | 6/38 | 6/42 | 8/41 | 7/40 |
| ConstipationGastrointestinal disorders | 2/38 | 5/42 | 7/41 | 7/40 |
| NauseaGastrointestinal disorders | 6/38 | 4/42 | 4/41 | 7/40 |
| HypertensionVascular disorders | 6/38 | 2/42 | 7/41 | 6/40 |
| Aspartate aminotransferase increasedInvestigations | 6/38 | 5/42 | 3/41 | 1/40 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/38 | 2/42 | 6/41 | 2/40 |
All randomized participants.
| Age, Continuous(years) | Ramucirumab Regimen 1 | Ramucirumab Regimen 2 | Ramucirumab Regimen 3 | Ramucirumab Regimen 4 | Total |
|---|---|---|---|---|---|
| Mean | 58.5 ± 14.0 | 58.7 ± 10.4 | 60.5 ± 12.3 | 56.2 ± 12.9 | 58.5 ± 12.4 |
| Sex: Female, Male(Participants) | Ramucirumab Regimen 1 | Ramucirumab Regimen 2 | Ramucirumab Regimen 3 | Ramucirumab Regimen 4 | Total |
|---|---|---|---|---|---|
| Female | 11 | 10 | 6 | 9 | 36 |
| Male | 29 | 32 | 35 | 32 | 128 |
| Ethnicity (NIH/OMB)(Participants) | Ramucirumab Regimen 1 | Ramucirumab Regimen 2 | Ramucirumab Regimen 3 | Ramucirumab Regimen 4 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 3 | 6 | 7 | 22 |
| Not Hispanic or Latino | 32 | 37 | 33 | 32 | 134 |
| Unknown or Not Reported | 2 | 2 | 2 | 2 | 8 |
| Race (NIH/OMB)(Participants) | Ramucirumab Regimen 1 | Ramucirumab Regimen 2 | Ramucirumab Regimen 3 | Ramucirumab Regimen 4 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 32 | 35 | 35 | 33 | 135 |
| More than one race | 6 | 7 | 5 | 6 | 24 |
| Unknown or Not Reported | 1 | 0 | 1 | 1 | 3 |
| Region of Enrollment(Participants) | Ramucirumab Regimen 1 | Ramucirumab Regimen 2 | Ramucirumab Regimen 3 | Ramucirumab Regimen 4 | Total |
|---|---|---|---|---|---|
| New Zealand | 2 | 1 | 1 | 3 | 7 |
| Argentina | 5 | 1 | 2 | 6 | 14 |
| Romania | 4 | 6 | 10 | 7 | 27 |
| Turkey | 3 | 4 | 2 | 2 | 11 |
| Hungary | 0 | 3 | 3 | 1 | 7 |
| United States | 2 | 3 | 2 | 1 | 8 |
| Poland | 6 | 6 | 7 | 5 | 24 |
| United Kingdom | 7 | 10 | 8 | 6 | 31 |
| Slovakia | 3 | 1 | 2 | 1 | 7 |
| Australia | 1 | 2 | 0 | 5 | 8 |
| France | 1 | 1 | 2 | 1 | 5 |
| Russia | 6 | 4 | 2 | 3 | 15 |
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and european union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Ran from Jul 2015 to primary completion in Nov 2016, 16 months.
Results were first posted in Mar 2018, 1 year 3 months after primary completion.
Of 65 industry-sponsored phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 68. This study's 16 months is below that.
Counting every sponsor, half of 360 studies reached it within 50 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ramucirumab